Dyne Therapeutics (NASDAQ: DYN) insider transactions
In the twelve months to 10 November 2026, executives and directors of Dyne Therapeutics reported 122 open-market sales of 7,611,963 shares ($168.6m) and 8 open-market purchases of 18,500 shares ($314,840), by 7 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 20 October 2026 | Kerr Douglas | Head of R&D and CMO | Grant or award | +8,000 | — | 170,564 | Form 4 |
| 2 October 2026 | Posner Brian S | Director | Open-market purchase | +2,500 | $16.00 | 27,000 | Form 4 |
| 8 September 2026 | Cox John | CEO & President | Open-market sale | −5,658 | $18.88 | 357,507 | Form 4 |
| 8 September 2026 | Kerr Douglas | Chief Medical Officer | Open-market sale | −1,290 | $18.88 | 162,564 | Form 4 |
| 8 September 2026 | Friedl-Naderer Johanna | Chief Commercial Officer | Open-market sale | −185 | $18.88 | 152,897 | Form 4 |
| 4 September 2026 | Kerr Douglas | Chief Medical Officer | Open-market sale | −3,745 | $24.35 | 163,854 | Form 4 |
| 4 September 2026 | Friedl-Naderer Johanna | Chief Commercial Officer | Open-market sale | −900 | $24.35 | 153,082 | Form 4 |
| 14 August 2026 | Rhodes Jason P | Director | Open-market sale, 10b5-1 plan | −1,359,674 | $25.00 | 2,441,454 | Form 4 |
| 14 August 2026 | Rhodes Jason P | Director | Open-market sale, 10b5-1 plan | −478,377 | $25.00 | 567,358 | Form 4 |
| 14 August 2026 | Rhodes Jason P | Director | Open-market sale, 10b5-1 plan | −322,465 | $25.00 | 428,946 | Form 4 |
| 13 August 2026 | Cox John | CEO & President | Open-market sale | −4,986 | $26.28 | 363,165 | Form 4 |
| 13 August 2026 | Rhodes Jason P | Director | Open-market sale, 10b5-1 plan | −268,354 | $26.20 | 3,801,128 | Form 4 |
| 13 August 2026 | Rhodes Jason P | Director | Open-market sale, 10b5-1 plan | −94,415 | $26.20 | 1,045,735 | Form 4 |
| 13 August 2026 | Rhodes Jason P | Director | Open-market sale, 10b5-1 plan | −63,643 | $26.20 | 751,411 | Form 4 |
| 13 August 2026 | Lucera Erick | Chief Financial Officer | Open-market sale | −1,797 | $26.28 | 119,766 | Form 4 |
| 13 August 2026 | Kerr Douglas | Chief Medical Officer | Open-market sale | −1,556 | $26.28 | 167,599 | Form 4 |
| 13 August 2026 | Friedl-Naderer Johanna | Chief Commercial Officer | Open-market sale | −226 | $26.28 | 153,982 | Form 4 |
| 27 July 2026 | Kersten Dirk | Director | Open-market sale | −256,072 | $25.50 | 3,592,184 | Form 4 |
| 27 July 2026 | Kersten Dirk | Director | Open-market sale | −5,388 | $26.04 | 3,586,796 | Form 4 |
| 7 July 2026 | Rhodes Jason P | Director | Open-market sale, 10b5-1 plan | −124,379 | $23.17 | 4,099,069 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Dyne Therapeutics page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.